Program
efgartigimod alfa
Also written as “Efgartigimod PH20 SC”, “efgartigimod PH20 SC” and “Efgartigimod IV”.
Its studies are mostly in Myasthenia Gravis · Purpura, Thrombocytopenic, Idiopathic · Pemphigus · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · Graves Disease, led by argenx.
Drug pageEfgartigimod alfa: every studyAll 66 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| argenx | 4817 open or running | phase 4since Oct 7, 2024 | Oct 20, 2016 | Mar 2027phase 3 · NCT04833894 |
Also a collaborator on its studies: IQVIA Pty, Zai Lab and Quintiles.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 35 earlier studies, Oct 20, 2016 to Mar 1, 2024.
- Dec 9, 2016Named efgartigimod alfaINNProposed as its International Nonproprietary Name in WHO's List 116 · before, ARGX-113
- Apr 26, 2024Phase 3 study in Myasthenia GravisNCT06392386 · 12 planned · United States, Australia, Belgium and more
- Jul 31, 2024Phase 3 study in Purpura, Thrombocytopenic, IdiopathicNCT06544499 · 69 planned · United States, Austria, Bulgaria and more
- Aug 14, 2024Phase 3 study in Myasthenia GravisNCT06558279 · 141 enrolled · United States, Australia, Austria and more
- Oct 7, 2024Phase 4 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingNCT06637072 · 23 enrolled · United States
- Oct 22, 2024Phase 2 study in Scleroderma, SystemicNCT06655155 · 87 enrolled · United States, Argentina, Belgium and more
- Nov 10, 2024Phase 3 study in Primary Sjogrens DiseaseNCT06684847 · 631 enrolled · United States, Argentina, Australia and more
- Mar 27, 2025Phase 4 study in New Onset Generalized Myasthenia Gravis (gMG)NCT06909214 · 30 planned · United States
- Sep 19, 2025Phase 3 study in Purpura, Thrombocytopenic, IdiopathicNCT07194850 · 24 planned · France, Germany, Italy and more
- Dec 8, 2025Phase 2 study in Myasthenia GravisNCT07284420 · 70 planned · United States, Belgium, Germany and more
- Apr 30, 2026Phase 3 study in Graves DiseaseNCT07570316 · 230 planned · United States, Georgia, United Kingdom
- May 7, 2026Phase 2 study in Autoimmune Diseases of the Nervous SystemNCT07583641 · 170 planned · United States
- May 13, 2026Phase 3 study in Graves DiseaseNCT07596849 · 230 planned · Belgium, Bulgaria, Canada and more
- Jul 29, 2026Phase 2 study in Sjogrens DiseaseNCT07760818 · 75 planned
- Oct 19, 2026Primary completion moved from 2026-10-01 to 2027-10Date moved laterphase 3 · +12 months · NCT04812925
Ahead
- Mar 2027Primary completion: phase 2 study in Scleroderma, SystemicNCT06655155
- Mar 2027Primary completion: phase 3 study in Myasthenia GravisNCT04833894
- Apr 30, 2027Primary completion: phase 2 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingNCT04280718
- Jul 2027Primary completion: phase 3 study in Primary Sjogrens DiseaseNCT06684847
TargetBeta
“IgG receptor FcRn large subunit p51 antagonist”ChEMBL 37, by rule
Other programs on FCGRT
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| rozanolixizumabrule | UCB | phase 4 | 23 |
| nipocalimabrule | Johnson & Johnson | phase 3 | 24 |
| batoclimabrule | immunovant-sciences-gmbh | phase 3 | 18 |
Studies
All 48 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07760818Sjogrens Disease | 2 | Not yet recruiting | Jul 28, 2028 | 75 |
| NCT07596849Graves Disease · Belgium, Bulgaria, Canada and more | 3 | Recruiting | Jun 2028 | 230 |
| NCT07583641Autoimmune Diseases of the Nervous System · United States | 2 | Not yet recruiting | Jul 2030 | 170 |
| NCT07570316Graves Disease · United States, Georgia, United Kingdom | 3 | Recruiting | Jun 2028 | 230 |
| NCT07284420Myasthenia Gravis · United States, Belgium, Germany and more | 2 | Recruiting | Mar 7, 2028 | 70 |
| NCT07194850Purpura, Thrombocytopenic, Idiopathic · France, Germany, Italy and more | 3 | Recruiting | Oct 2028 | 24 |
| NCT06909214New Onset Generalized Myasthenia Gravis (gMG) · United States | 4 | Recruiting | Aug 2026 | 30 |
| NCT06684847Primary Sjogrens Disease · United States, Argentina, Australia and more | 3 | Active, not recruiting | Jul 2027 | 631 |
| NCT06655155Scleroderma, Systemic · United States, Argentina, Belgium and more | 2 | Active, not recruiting | Mar 2027 | 87 |
| NCT06637072Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States | 4 | Completed | Feb 19, 2026 | 23 |
| NCT06558279Myasthenia Gravis · United States, Australia, Austria and more | 3 | Active, not recruiting | Jan 12, 2026 | 141 |
| NCT06544499Purpura, Thrombocytopenic, Idiopathic · United States, Austria, Bulgaria and more | 3 | Recruiting | Jun 2028 | 69 |
| NCT06392386Myasthenia Gravis · United States, Australia, Belgium and more | 3 | Recruiting | Sep 2027 | 12 |
| NCT06307626Graves Ophthalmopathy · United States, Austria, Bulgaria and more | 3 | Terminated | Dec 15, 2025 | 105 |
| NCT06307613Graves Ophthalmopathy · United States, Australia, Belgium and more | 3 | Terminated | Dec 15, 2025 | 102 |
| NCT06298552Myasthenia Gravis · United States, Belgium, Canada and more | 3 | Active, not recruiting | Jun 30, 2025 | 119 |
| NCT06203457Primary Sjögren's Syndrome · Belgium, Hungary, Poland | 2 | Completed | Feb 3, 2025 | 24 |
| NCT05979441Myositis · United States, Argentina, Austria and more | 3 | By invitation | Sep 2028 | 240 |
| NCT05927415Renal Insufficiency · Germany | 1 | Completed | Jun 12, 2024 | 33 |
| NCT05918978Post-COVID Postural Orthostatic Tachycardia Syndrome Postural Orthostatic Tachycardia Syndrome · United States | 2 | Terminated | Aug 15, 2024 | 33 |
| NCT05810961Glomerulonephritis, Membranous · China | 2 | Terminated | Aug 5, 2024 | 8 |
| NCT05817669Primary Sjögren's Syndrome · Belgium, Hungary, Netherlands and more | 2 | Completed | Jan 29, 2024 | 34 |
| NCT05810948Lupus Nephritis · China | 2 | Completed | Jul 2, 2025 | 73 |
| NCT05681481Pemphigoid, Bullous · United States, Australia, Bulgaria and more | 3 | Terminated | Mar 20, 2025 | 64 |
| NCT05633407Postural Orthostatic Tachycardia Syndrome · United States | 2 | Completed | Apr 18, 2024 | 53 |
| NCT05267600Pemphigoid, Bullous · United States, Australia, Bulgaria and more | 3 | Completed | Sep 13, 2024 | 98 |
| NCT05163834Healthy Volunteers · Netherlands | 1 | Completed | Mar 8, 2022 | 36 |
| NCT04980495Myasthenia Gravis · United States, Austria, Belgium and more | 3 | Completed | Aug 24, 2023 | 69 |
| NCT04833894Myasthenia Gravis · United States, Austria, Belgium and more | 3 | Active, not recruiting | Mar 2027 | 15 |
| NCT04812925Purpura, Thrombocytopenic, Idiopathic · United States, Argentina, Australia and more | 3 | Active, not recruiting | Oct 2027 | 173 |
| NCT04818671Myasthenia Gravis · United States, Belgium, Czechia and more | 3 | Completed | Dec 31, 2024 | 184 |
| NCT04735432Myasthenia Gravis · United States, Belgium, Georgia and more | 3 | Completed | Nov 2, 2021 | 110 |
| NCT04687072Purpura, Thrombocytopenic, Idiopathic · United States, Argentina, Australia and more | 3 | Completed | Oct 9, 2023 | 207 |
| NCT04598477Pemphigus · United States, Australia, Bulgaria and more | 3 | Terminated | Mar 25, 2024 | 183 |
| NCT04598451Pemphigus · United States, Australia, Bulgaria and more | 3 | Completed | Aug 22, 2023 | 222 |
| NCT04564066Healthy Volunteers · Netherlands | 1 | Completed | Dec 24, 2020 | 54 |
| NCT04280718Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Austria, Belgium and more | 2 | Active, not recruiting | Apr 30, 2027 | 229 |
| NCT04274452Purpura, Thrombocytopenic, Idiopathic | 3 | Withdrawn | Sep 1, 2021 | 0 |
| NCT04225156Purpura, Thrombocytopenic, Idiopathic · United States, Austria, Belgium and more | 3 | Completed | Mar 11, 2026 | 101 |
| NCT04188379Purpura, Thrombocytopenic, Idiopathic · United States, Austria, Belgium and more | 3 | Completed | Feb 3, 2022 | 131 |
| NCT04073589Healthy Volunteers · Netherlands | 1 | Completed | Sep 26, 2019 | 33 |
| NCT03770403Myasthenia Gravis · United States, Belgium, Canada and more | 3 | Completed | Jun 23, 2022 | 151 |
| NCT03669588Myasthenia Gravis · United States, Belgium, Canada and more | 3 | Completed | Apr 6, 2020 | 167 |
| NCT03457649Healthy Volunteers | 1 | Completed | Nov 15, 2016 | 62 |
| NCT03334084Bioavailability Study · Netherlands | 1 | Completed | Sep 19, 2018 | 40 |
| NCT03334058Pemphigus · Germany, Hungary, Israel and more | 2 | Completed | Oct 28, 2020 | 34 |
| NCT03102593Purpura, Thrombocytopenic, Idiopathic · Austria, Belgium, Czechia and more | 2 | Completed | Apr 9, 2019 | 38 |
| NCT02965573Myasthenia Gravis · United States, Belgium, Canada and more | 2 | Completed | Oct 20, 2017 | 24 |
How it is read
Names in the registry
- “Efgartigimod PH20 SC”, 12 entries
- “efgartigimod PH20 SC”, 10 entries
- “Efgartigimod IV”, 7 entries
- “ARGX-113”, 7 entries
- “Efgartigimod”, 5 entries
Conditions, from the studies’ own filings
- Myasthenia Gravis, 12 studies
- Purpura, Thrombocytopenic, Idiopathic, 8 studies
- Pemphigus, 3 studies
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, 2 studies
- Graves Disease, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.